RC
BEAM icon

Renaissance Capital’s Beam Therapeutics BEAM Stock Holding History

Renaissance Capital’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-23,223
Closed -$908K – 89
2022
Q4 		$908K Buy
+23,223
New +$1.04M 0.71% 42
2022
Q2 		– Sell
-15,955
Closed -$914K – 75
2022
Q1 		$914K Sell
15,955
-4,775
-23% -$313K 0.39% 58
2021
Q4 		$1.65M Sell
20,730
-2,996
-13% -$257K 0.42% 52
2021
Q3 		$2.06M Buy
+23,726
New +$2.38M 0.42% 48

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Renaissance Capital's BEAM Position: Q1 2023 in Review

Renaissance Capital sold out of Beam Therapeutics (BEAM) in Q1 2023, closing a stake of 23,223 shares — an estimated $908K sold.

Renaissance Capital first reported a position in BEAM in Q3 2021 and held it in 4 quarters. The position peaked at $2.06M in Q3 2021. 206 funds tracked by Wall St. Rank hold BEAM as of Q1 2023.

  • Renaissance Capital reported no remaining Beam Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Renaissance Capital sold 23,223 Beam Therapeutics shares in Q1 2023, an estimated $908K.
  • Renaissance Capital first reported a position in Beam Therapeutics in Q3 2021 and held it in 4 quarters.
  • Renaissance Capital's Beam Therapeutics position peaked at $2.06M in Q3 2021.
  • 206 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2023.

Based on Renaissance Capital's 13F filing for Q1 2023, filed 11 Apr 2023.